|
|||||
|
|
A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects |
|
| Authors: | W. Krauwinkel PharmD MS J. Noukens MSc J. van Dijk BS S. Popa MD PhD T. Ouatas PhD M. de Vries PhD PharmD D. Phung BS J. Gibbons PhD J. Mordenti PhD L. Mateva MD PhD MS |
| Affiliation: | 1. Astellas Pharma Europe, Leiden, The Netherlands;2. Kinesis Pharma BV, Breda, The Netherlands;3. ARENSIA Exploratory Medicine, Republican Clinical Hospital, Chisinau, Moldova;4. Medivation, Inc., (Medivation was acquired by Pfizer, Inc. in September 2016), San Francisco, CA, USA;5. Gastroenterology Clinic, University Hospital St. Ivan Rilski, Medical University Sofia, COMAC Medical Ltd, Sofia, Bulgaria |
| Abstract: | |
| Keywords: | clinical pharmacokinetics liver metabolism |